hotspot -WSS

hotspot

author：explore 2025-09-06 04:27:29 - browse：43

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Problems with a popular proposal to regulate AI in health care

entertainment

WSS

Top private equity targets in 2023: cardiology, clinical trials, lasers

Global cancer cases to surge 77% by 2050, WHO report says

Being 'nonadherent' patient made me a more empathetic doctor

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Beware reading your test results before your doctor does

The Biogen Aduhelm mess could happen again

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Hollywood unions extend contract negotiations for actors

Surgery pushed Ben Carson to fame

Activists slam private health insurers over coverage restrictions

What affirmative action's end means to a medical student

The high cost of giving birth even with insurance

Unique patient identifier: Experts argue the benefits, pitfalls

Supreme Court strikes down use of affirmative action

Undocumented workers face uncertainty as immigration law takes effect in Florida

Wildfire smoke exposes gaps in outdoor worker protections

Problems with a popular proposal to regulate AI in health care

Wikipedia

Security flaws in third

Skip the lead apron during X

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

AI gets buy

Wikipedia

entertainment

hotspot

leisure time